A pair of researchers from Harvard Medical School call for reforms to the Orphan Drug Act to help stem rising drug prices. They suggest revoking the seven-year exclusivity period when orphan drugs are already available in other markets, including the European Union, or requiring that certain manufacturers repay the tax credits and research grants they received for developing a drug for a rare disease. But the head of the National Organization for Rare Disorders warns against policymakers dismantling what the...